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CHAPTER I
INTRODUCTION

Hesse, in 1927 (l), "was perhaps the first to show that FlexnerJobling rat carcinoma

could be transmitted by the ascitic fluid that

developed during the growth of the tumor.

Koch (2), one year later, con

firmed this finding and also showed that the tumor developed better when
injected intraperitoneally, and that the number of tumor cells in the
ascitic fluid increased with time. In 1932, Lowenthal and Jahn (3), Koch's
collaborators, obtained on injection of Ehrlich mouse carcinoma, an
ascites-producing tumor instead of the usual solid tumor. This ascites
tumor could be transplanted successfully through intraperitoneal injection
of the ascitic fluid. Thus Lowenthal and Jahn (3) established a new line
of the Ehrlich carcinoma, which they called the ascites tumor. This
ascites tumor found wide use in experimental studies in Germany soon after
it was discovered (4, 5, 6, 7), and in recent years it has been widely
employed for other studies. Lettre (5), for example, used it to study
chemotherapeutic agents, Klein and co-workers (8) studied its chemical
composition, and Warburg and Hiepler (6) studied its metabolism. Hauschka
and Levan (9) and Hauschka (10) recognized the extraordinary significance
of this ascites tumor as a convenient material for the study of chromo
somes, cell morphology and tumor transplantation immunity.
In 1948, Klein and co-workers (11) converted a solid line of
Ehrlich mouse carcinoma into the ascitic form and named it the
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tetraploid line of Ehrlich mouse ascites carcinoma. Since then a wide
variety" of transplantable tumors have been converted into the ascitic
form. Interesting types of ascites tumor have been reported by
Craigie (12), Makino (13), Tanaka (lU), Takeda (15), SheIton (l6),
Isaka (17), Bather (18), Williams (19), and Fekete and Griffen (20).
The general characteristics of the Slirlich mouse ascites tumor
have been studied by Klein and co-workers (21). After an animal is
given an intraperitoneal injection of the tumor fluid, it develops a
progressive ascites.

The time required for the ascites to become

manifest varies inversely with the number of cells in the inoculum.
With the usual dose of 0.1 ml of the ishole fluid (approximately
9 X 10^ cells), it takes 6 to 8 days for the ascites to become grossly
noticeable. With lower doses it may take as long as twenty days
before any ascites is recognizable, and if the dose is much lower,
ascites may not be produced at all,' Instead, a solid implantation and
growth occur on the omentum or some other part of the peritoneal
membrane (21).
The morphology of the Ehrlich ascites tumor cells has been
studied by phase microscopy, ordinary light microscopy (22) and
electron microscopy (23). Under the phase microscope, the tumor cells
display fine hair-like pseudopodia averaging about 1 micron in length,
a well defined nucleus with irregularly clumped chromatin, and the
cytoplasm. The cytoplasm contains two readily distinguishable
componentss

1) the mitochondria that appear as short dark rodlets and

2) sees brilliantly refractile globules that contain large amounts of

-3lipxd (23).

In 1958, Hirono and Iwao (2U) reported that the living

Ehrlich ascites tumor cells when observed in hanging drop preparations,
after incubation at 37° G for 1 hour, display ameboid movement and
pseudopod formation. The average measured motility of the cells was
about 0.9 microns per minute.
Studies mth stained preparations (2$, 26, 27) have shown that
the nucleus contains several prominent nucleoli. Inside many of these
nucleoli there are fine vacuoles. In addition to the nucleoli and the
chromatin, the nucleus also contains finely granular parachromatin (26)
which stains acidophilic. In old tumors, the chromatin and the para
chromatin of an occasional cell are marginsted and 1 or more acido
philic bodies are formed.

The nature of these bodies is made clear

by the use of toluidine-blue-molybdate stain (27), which stains the
desoxynucleoprotein content of the cell»

By this method the desoxy-

nucleoprotein of the parachromatin stains purple and that of the
nucleolus green. Many of the nucleoli contain metachromatic
ribonucleoprotein bodies or nucleolini (28), which appear to corre
spond to the vacuoles seen in other preparations. Under the microscope
it can be seen that the large inclusions consist of a homogeneous
green-staining center,derived from the nucleolus, covered by purple
parachromatin granules. In degenerating cells smaller inclusions
appear to be entirely formed by condensation of the parachromtin, A
study of the old ascites tumor cells reveals that these cells eventu
ally degenerate and disintegrate, going through the conventionally
recognized processes of pyknosis, karyorrhexis and karyolysis, after

which the fragments are digested by the macrophages.
The cytoplasm of the Ehrlich ascites tiimor cell contains 3 types
of lipid particles (25). Seme of these particles are large droplets
which stain red with Nile-blue sulfate. These are especially predom
inant in older degenerating cells and cells that are infected with
viruses (29, 30, 31). The second type of lipid droplets consists of
an amorphous, acidic, Schiff-periodic acid-positive material found
chiefly in the perinuclear zone of the cytoplasm. These granules
consist mainly of phospholipids (32), and are found in the region
where the golgi apparatus is located (22). Like the golgi apparatus,
these phospholipid granules also are stained by the Kolatchew golgi
apparatus staining technic (33)»

The third type of these lipid

particles in the cell consists of the mitochondria. These are more
regular in shape and are distributed more evenly than the former
particles in the cytoplasm (34). In the degenerating cells of the old
tumors, neither the mitochondria nor the golgi apparatus are altered
significantly except during the final stage of disintegration of the
cell.
Studies of the cellular component of the ascites at different
phases of growth of the tumor, have shown that the cells consist
mainly of tumor cells, but red blood cells and inflammatory cells are
also present. The relative proportion of the red cells varies.

Some

fluids are grossly hemorrhagic while others are relatively clear. The
red blood cells present in the fluid display poikilocyfcosis and
hypochranesia (35). Fair proportion of these are also nucleated. The

-5proportxon of inflammatory cells varies with the individual animal and
with the age of the tumor. Generally in early stages of growth the
percentage of non-tumor cells has been found to be inversely related
to the number of tumor cells in the inoculum (21), A variation in the
physiological ages of the inocula has little or no effect on cell
count. The latent period (l,e., the period preceding the actual
increase in the cell count) is prolonged when older inocula are used,
Klein and co-workers (21) investigated the tumor growth using 3-j 6-,
and l6-day-old fluid as inocula. They collected the fluid after a
definite period, rinsed the peritoneal cavity twice with saline and
determined the total volume of fluid and number of cells per animal.
Thus they were able to determine the various phases of growth of the
Ehrlich mouse ascites tumor. These phases ares

l) the latent phase,

2) the phase of logarithmic growth, 3) the stationary phase in which
more fluid than cells is formed and It) the regression phase during which
the dead cells predominate.

They reported that with inocula of various

ages, the growth curves were more or less parallel, and the difference
between regression phases was not at all marked. On the basis of these
observations, Klein concluded that the physiological age of the inoculum
has no discernible effect on the proliferation of the tumor cells.
The tumor cell population consists of both living and dead tumor
cells. They can be differentiated by staining a wet smear of fresh
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fluid with nigrosin (36). The living cells take up the vital stain
and are consequently stained black.

The dead cells remain unstained.

The tumor cells have been counted in different ways by different
workers. Hemocytometric counting chambers have been employed most
successfully and conveniently (21), An ascitocrit, a modification of
a hematocrit, is the next most widely employed tool for this purpose
(37)»

Klein and co-workers using the hemocytometer have reported the

tumor cell count of the ascitic fluid at different stages of growth of
the tumor (21), These workers found that after a latent period of
about ii.8 hours, the cell count started rising more or less logarith
mically till it reached the peak on or about the 9th day. The
inflammatory cells were a predominant feature of the ascitic fluid
during the latent period. From the 9th to the 11th day the cell
count was relatively stationary. Since the amount of fluid produced
was very high at this stage, "Uie cells were diluted and the count was
low per unit volume (about 1 x 10® cells per ml) as compared to the
cell count at the peak of the growth curve (2-3 x 10® per ml). After
the 11th day the phase of regression ensued where the proportion of
dead cells increased (21).
The fluid component of the ascites increased progressively as the
infection proceeded. Tlïhen 0.1 ml of the whole fluid was used as
inoculum, the fluid varied from 5 to 8 ml on the 6th day to 12 to
l5 ml on the 16th day*

The protein content of this ascitic fluid was

lower than that of serum from tumor-bearing mice (3.1 gm % in fluid

-7and ii.9 gm ^ in serum).

The serum from normal mice contains 6,7 gm of

protein per 100 ml. The albumin content of the ascitic fluid nvas
especially low (0,9 gm %). The concentration of alpha- and gamma
globulins was also lower when coiqpared with the serum (38). However,
the beta-globulin level was higher (1,1 gm %) in the ascitic fluid than
in the sera of mice bearing the tumor (0.6 gm^). The properdin titer
of ascitic fluid was never more than ii,0 units per ml, whereas the serum
of tumor-bearing mice contained 10 to hO units of properdin per ml.
The most obvious effect of tumor growth on the host is the pro
duction of ascites»

This ascites formation leads to respiratory

embarrassment5 toxemia, hepatic dysfunction, renal insufficiency and
finally death. In 1933s Putnoky (35) followed the changes in the
peripheral blood in rats after injecting the tumor intra peritoneally,
He noticed a rise in polymorphonuclear count accompanied by a simultan
eous fall in the number of the lymphocytes. Monocytes and eosinophils
also decreased in number. The platelet count showed a transient rise.
Anemia was a marked feature and the red blood cells displayed anisoeytosis, poikilocytosis and polychromatophilia.

Nucleated red cells

and reticulocytes were abundant. Coagulability of the blood was
unaffected, Putnoky (35) also reported that these changes were
reproducible with autolysates, emulsions and ethereal extracts of
necrotic tumor cells.
The literature on tumor immunity is so extensive that even as
early as 1916, lyzzer (39) stated that "It is quite impossible to
present within reasonable space, a comprehensive review of all

-8investigations done on tumor-immunity," A second review by Waglom in
1929 contained over six hundred references (ij.0).
Specific immunity to transplantable tumors is the reaction of an
organism to a foreign cell. Bie degree of this reaction or immunity
depends on the foreign-ness of the tumor cells.

Much work has

been done in this field, Caspari in 1929 (l&l)^ introduced the
concept of "necrohormones" which he thought were produced as a
result of degeneration of the tumor and caused the development
of a general immunity. Lumsden, (1^2) in 1931, went to the extent
of saying that "There is no antibody whose existence is more
proved than that of these anti-malignant-cell antibodies." He
described five types of antibodies against tumor cells; 1) antispecies antibody, 2) homologous cytotoxins, 3) normal heterocytotoxins, k) autocytotoxins, and 5) cytotoxins for malignant
cells present only in animals with tumors. In 1937, however,
Phelps (ii.3) showed that the antibodies of the so-called antisera of Lumsden had no specific action on the cancer cells and
were not peculiar to the malignant cells. He described them
as isoantibodies in response to foreign though homologous cells
that were injected.
Gprer (iiU, hS) introduced the idea that genes were respon
sible for isoantigenic differences and showed that certain important
isoantigens were shared by mouse erythrocytes, normal fixed tissues

and the tumor cells, Hauschka (10) postulated that successful trans
plantation of a graft depended on the simultaneous presence of dominant
genes, in the graft as well as in the host. He also said that this was
true for normal as well as for neoplastic tissues. If a tumor graft
carries one or more dominant loci functioning in the direction of
elaboration of cellular antigens, and the host has inactive or immuno
logically different alleles of these genes, the implant evokes
antibodies against itself and usually regresses. If on the other hand
the pertinent antigenic alleles are dominant in both the tumor and the
host, no immune reaction ensues, and the tumor transplant continues to
grow.
It has been shown that most of the malignant cells contain
various antigens (I4.6, klf U8, h9s 50), some of which are common to
normal tissues. Various reports have appeared I'egarding the demon
stration of specific neutralizing and/or agglutinating antibodies
against different tumors.

Neutralizing antibodies against Rous Sarcoma

were described in the sera of recovered chickens by Kabat and co
workers (5l). Kidd demonstrated neutralizing antibodies against BrownPearce carcinoma (52) and Shope papilloma (53).

Bennison (5%) and

Imagawa (55) demonstrated antibodies against Bittner milk agent for
mammary carcinoma. Flax (80) and Horn (81) reported the successful
neutralization of the carcinogenic property of Ehrlich ascites tumor
cells by incubating them with rabbit antiserum. Flax, however, could
not demonstrate any in vitro neutralization without the addition of
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guinea pig complement to the antiserum. The gamma-globulin fraction of
this antiserum ivhen combined with guinea pig complement could also
neutralize the tumor (80), Treatment of this gamma-globulin-complement
complex at $6^ G for 30 min

destroyed its neutralizing power, Horn

(8l) was able to demonstrate neutralization of the tumor without the
addition of complement. Flax also observed that the average survival
period of the tumor-bearing mice was almost doubled when they were
treated with the antiserum or gamma-globulin fraction of this antiserum
after challenge.

Recently Sukhorukikh (82, 83, 8i^) demonstrated a

definite cytotoxic effect of agglutinating antiserum on the tumor cells.
The same author (83) also demonstrated the inhibition of mitotic activ
ity of the tumor cells after incubation with the agglutinating anti
serum,

Normal rabbit serum and antisera prepared against liver and

spleen from normal mice, failed to produce this inhibition.
Snail and his associates (56) showed that dead tissue or tissue
products could be used as active immunizing agents against trans
plantable tumors,

Tizzoni and co-workers (57)5 in 1930, used malignant

cells killed with formalin and phenol to immunize mice against an
adeno-carcinom (8281). Bittman and Goldfeder in 1929 (58) prepared
antisera against Shrlich mouse carcinoma and demonstrated that mice
injected with this antiserum before tumor transplant were not protected,
while if "tJie antiserum was given after the tumor, there was a slight
inhibitory effect. Gostero in 1930 (59) made attempts to immunize mice
against Ehrlich mouse carcinoma by injecting intravenously autolysates

-11of muscles from cancerous mice but was not successful. Schabad in 19.39

(60) reported that addition of splenic tissue from normal mice inhib
ited the growth of Ehrlich mouse carcinoma, whereas spleen from
cancerous mice lacked this property. Lund (61) in 19^8, was successful
in immunizing rats against ïoshida sarcoma by intracecal injection of
tumor cells. Recently Donaldson and Mitchell (62) immunized 90% of
mice against Ehrlich ascites tumor by using tumor cells killed with
x-rays5 and Donaldson and North (63) immunized mice against this tumor
by using tumor cells killed with nitrogen-mustard.
Before closing this chapter, the subject of non-specific immunity
to tumors will be briefly reviewed. It is known that administration of
neutral polysaccharides of diverse plant, animal and microbial origins
to experimental animals profoundly affects the resistance to bacterial
infection and growth of tumor transplants. Large doses of zymosan or
bacterial polysaccharides transiently decrease the resistance of mice
to gram-negative bacterial infection (6L, 65) and cause increased
growth and lethality of Sarcoma 180 in mice (66), human epidermoid
carcinoma in rats (67), and human intestinal adenocarcinoma in rats
(68).

Conversely, small doses of polysaccharides increase the

resistance of mice to infection (65, 69^ 70, 71, 72, 73) and increase
the rejection of Sarcoma 180 (66, 7k) and Sarcoma 37 in mice. Lack of
cross-antigenicity between zymosan and these pathogens indicates that
these effects are the result of an initial depression followed by
stimulation of non-specific host defense mechanisms. The effect of

-12polysaccharides on susceptibility to infection and tumor growth varies
inversely as its effect on serum properdin levels (70, 71, 7U),
suggesting that properdin, or another defense mechanism which fluc
tuates simultaneously with properdin, may be involved in tumor rejection
mechanism*

Kidd (76), Ainis (77) and Herbut (78) have demonstrated in

guinea pig serum a non-specific humoral factor, probably different from
complement and properdin, which inhibits the growth of a rat
lymphosarcoma.
To summarize the issue of immunity and cancer, Southam (79) may be
quoteds

"In spite of the complete absence of proof, the existence of

so many suggestive bits of clinical and experimental data sustains the
working hypothesis that cancer is not a wholly autonomous growth but
may be susceptible to restraint by the host mechanisms,"

CHAPTER II

STATEMENT OF PROBLEM

From the review of the literature, it appeared reasonable to assume
that tumor transplants are influenced by the host defense mechanisms
which could be modified by specific and non-specific means. With this
assumption in mind, it was decided to study: 1) active immunization of
mice by the use of Ehrlich ascites tumor cells treated with different
physical and chemical agents, 2) passive immunization by the use of
Ehrlich-ascites-tumor-cell-agglutinating rabbit antiserum, and 3) non
specific immunization induced by Bordetella pertussis cells, zymosan,
Escherichia coli endotoxin and Freund's incomplete Bacto-adjuvant.
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CHAPTER III

MATERIALS AND METHODS

MATERIALS:
Tumor?

A line of the ascitic form of Ehrlich ascites tumor was

obtained from Dr. P. C. Rajam of the University of Michigan on May 9,
1959, and ms maintained in the Stella Duncan Laboratory, Montana State
University, through weekly intraperitoneal transfers in female mice.
Mice; In most of the experiments, 5- to 7-week old mice of the CFW
(Swiss Webster) strain purchased from Carworth Farms, New City, New York,
were used. In some experiments, the strain of white mice kept at the
Rocky Mountain Laboratory, Hamilton, Montana, was used.
Rabbits; Male rabbits weighing between 4 and 6 pounds were used for
preparing the antiserum.

These rabbits were of undetermined strain, and

were purchased from the Dry's Rabbit Farm, Veradale, Washington.
Physiological saline;

0.85% sodium chloride in distilled water is

referred to as physiological saline.
FormalinÎ

36.3^ formalin solution, lot No. 545228, obtained from

the Fisher Scientific Company was used.
Phenol; Crystalline phenol, lot No. 90851, obtained from the J. T.
Baker Company was used.
Merthiolate: 1:1,000 merthiolate (thimerosal), lot No. 6133-738850,
containing 0.1$ monoethanolamine and obtained from Eli Lilly Company was
used.

-14-

-15Freund's Adjuvant; 10,0 ml ampoules of Freund's Incomplete Bactoadjuvant, lot No, 0639-60, control hh3^05 purchased from the Difco
Laboratories were used.
Bordetella pertussis Cells;

Cells were grown in the liquid medium

of Verwey at al. (88), and were killed by the addition of 0.01%
merthiolate. These merthiolate-killed cells were kept in a suspension
containing 700 billion cells per ml in saline with 0.01% merthiolate,
Escherichia coli Lipopolysaccharideî

Batch No. L583-362, 10-1,

obtained from Merck Sharp and Dohme Company through the courtesy of
Dr. 0. Ganley was used.
Zymosans Lot No. 71313, obtained from the Fleischmann Laboratories,
Betts Avenue, Stanford, Connecticut, was used.

METHODSs
Collection of Fluids

From the growth curves obtained in mice

inoculated with 0.2 ml of Shrlich mouse ascites tumor fluid, it can be
said that the maximum number of cells (about 1 x 10^ per ml) is
obtained around the 8th day after the inoculation. At this stage, the
number of dead tumor cells and inflammatory cells is at its lowest
point (21), For these reasons, the tumor fluid for all experimental
purposes (unless stated otherwise) was collected by tapping the mice
on the 8th day after the tumor inoculation. The tapping was done with
an 18 gauge sterile needle inserted in the region of the left iliac
fossa, !Hie fluid was allowed to flow out into a test tube. On many
occasions the needle was removed and the fluid allowed to flow out of

—l6—

the puncture wound.

The fluid thus obtained was stored in the refrig

erator or used immediately. In no case was a sample of fluid stored
for more than 18 hours, as it has been shown that after 30 hours in the
refrigerator, most of the cells are dead.
Washing the Tumor Cells?

Tumor cells were obtained reasonably

free from fibrin clots and necrotic debris by centrifuging the whole
fluid at a rate of 2,000 rpm for 5 min at 6° G in a model S-8 Servall
centrifuge. The turbid supernatant was pipetted off, mixed with an
equal volume of physiological saline, and centrifuged at 5,000 rpm for
5 min. The sedimented cells were resuspended in saline and mixed
thoroughly. Then they were spun down again. This was repeated $ times
or until the cells ceased to form sticky clumps (85). Cells properly
washed went into suspension rather easily.
Standardization of Cell Suspensions?

Serial tenfold dilutions of

the cells were made in saline by adding 0.5 ml of suspension to

ml

of saline. The third and fourth dilutions were counted in a
Heubauer-type Hemocytometer counting chamber. The cell content was
calculated as followss
Total cell count in the four chambers x 10 - No. of cells
It
~ ~ per cu mm
Suspensions for Challenge;

The fluid for this purpose was usually

obtained from a female CFW mouse that had received the tumor 8 to 10
days previously. Dilutions were made in saline to give a final cell
count of 20,000 per ml. Four to six thousand cells (0,2 to 0,3 ml)
were injected intraperitoneally. The suspension was injected within

-17half an hour after making the dilutions in order to avoid any serious
injurious effect of saline on the tumor cells. This dosage of ij.,000
to 6,000 cells was chosen because it was shown that the ascites became
manifest by the 20th day after this challenge. With lower doses the
incidence of the tumor in ascitic form was lower and ascites became
apparent only after a longer period of time (3^ to l+O days).
Treatment with formalinî

Cells were separated from 5.0 ml of

fluid and washed 3 times with saline. Then they were resuspended in
saline to a final concentration of 5 x 10^ cells per ml.

To ii,0 ml of

this suspension contained in a 25 ml pyrex glass beaker were added
O.Oli ml of formalin and l6.0 ml saline. The suspension was thoroughly
mixed and allowed to stand at room temperature for 2 hours with
occasional manual agitation, and then kept in the refrigerator for 16
hours. At the end of this period this cell suspension was used to
vaccinate mice. Freshly formalinized cells were used for each
vaccination.
Treatment with phenol: Saline-washed cell suspensions containing
5 X 10^ cells per ml were made as for the preparation of formalinized
cells. The cells from 20,0 ml of this suspension were separated by
centrifligation and re suspended in 20.0 ml of 0.8# phenol in a 50 ml
pyrex glass beaker. This suspension was thoroughly mixed and allowed
to stand at room temperature for 1 hour and then in the refrigerator
for 18 hours. At the end of this time, the cells were separated and
washed twice with saline to remove excess phenol, and then resuspended

-18in 20.0 ml of saline.

This suspension was used to vaccinate mice.

Freshly treated cells were used for each vaccination.
Treatment with merthiolate; A washed cell suspension containing
5 X 10^ cells per ml was prepared as above. Three ml of this suspension
were added to a 25 ml beaker containing 5,0 ml of saline and 2,0 ml of
1*1000 merthiolate. This su&pension was allowed to stand at room
temperature for 2 hours with frequent shaking, and then kept in the
refrigerator for 16 hours. At the end of this period, the suspension
was used to vaccinate mice. Freshly prepared merthiolate-treated cells
were used for each vaccination.
Preparation of disrupted cells?

Approximately ij. gm of No, 12

Cataphote glass beads and 5.0 ml of a saline suspension of cells con
taining 5 X 107 cells per ml were placed in a Mickle reed and shaken
in a Mickle disintegrator for li min. This was repeated U times with 5
to 10 min intervals between each treatment. Samples were examined
under the microscope to determine the degree of disruption. If less
than 80% of the cells were disrupted, the mixture was shaken once more
for ii min. Then the glass beads were allowed to settle and the broken
cell suspension was pipetted off, When only cell extract was desired,
this suspension kept at 6° C was centrifuged at 8,000 rpm for 10 min
and the supernatant was decanted and again similarly centrifuged to
remove the cell debris.
Irradiation with ultraviolet light?

A G15-8T model ultraviolet

lamp (2,537 A) purchased from the General Electric Company was used.

-19No exact measure of the ultraviolet light intensity emitted from this
lamp was made and for this reason it is not possible to specify in
exact terms the dose of ultraviolet light administered to the tumor
cells. To vary the dose, only the time of exposure was varied. The
procedure used was as follows;
Two and one-half ml of the tumor fluid were diluted ten times by
adding 22.5 ml saline. Ten ml of this diluted fluid were placed in a
glass petri dish 9.0 cm in diameter. After allowing the lanp to warm
up for 15 min, the dish containing the fluid was placed on a platform
at a distance of 30 cm below the center of the laiip. This platform was
mechanically rocked to keep the fluid under constant agitation.
Samples of fluid were irradiated for 10 and 15 min^ and then injected
into mice within 15 min after irradiation. The energy emitted by the
lamp under the specified conditions was approacimately 32.3 ergs/ram2/sec
(86)*

ThereforeJ the energy derived from 10 min irradiation was approx

imately 10 X 60 X 32.3 or 19,380 ergs/mm^j and that from 15 min
irradiation, 20,070 ergs/mm^.
Immunization of rabbits; Six rabbits were divided into 2 groups
of 3 eachj group I received intact tumor cells and group II received
disrupted cells. Thirty ml of blood was collected from each rabbit
before starting the immunizing injections. Then they were given
subcutaneous injections of 2,0 ml of the immunizing material (washed
cells in saline with 9 x 10^ cells per ml or 2,0 ml of the broken-cell
suspension). These injections were given at three-day intervals for a
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total of 9 injections. Thereafter the rabbits were trial-bled from the
margixial ear vein at three-day intervals^ and the serum agglutinin
titer determined. The titer reached its peak on the 26th day after the
last injection and then it started to decrease. On the 28th day the
rabbits were given another subcutaneous dose of 2,0 ml of unbroken
washed cell suspension containing 9 z 10^ cells per ml. The
agglutinin titer was again followed. Fifteen days after the booster
dose, when the agglutinin titer was high, the rabbits were bled to
death from the heart. The serum was obtained and stored in the frozen
state (-20° C).
Agglutinin titrations

Serial two-fold dilutions of the antiserum

were made in 1*100 normal rabbit serum in saline. Saline and 1(100
normal rabbit serum in saline were used as controls. To 0,5 ml of the
respective dilutions, 0,5 ml of a suspension of tumor cells (washed
four times) in saline containing it x 10^ cells per ml was added. The
tubes were thoroughly shaken and allowed to stand at room temperature
for 2 hours and then overnight in the refrigerator. The results were
then recorded as -,

ff-f, & ffj-f depending on the degree of

clumping of the tumor cells noticed after shaking the tubes gently.
In reading this agglutination every tube was compared with the normal
rabbit serum and the saline controls.
Technic of absorption of the rabbit antiserum;
A. Specific absorption with washed tumor cells;

Tumor cells

obtained from 5.0 ml of ascites fluid were washed h times with saline
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and then sedimented»

These sedimented cells were then added to 12,0 ml

of rabbit antiserum (titer 1g2560), mixed thoroughly and allowed to
stand in the refrigerator.

Twenty-four hours later, the antiserum was

separated by centrifuging at 12,000 rpm for 15 min. Fresh tumor cells
obtained from 5*0 ml of ascites fluid were washed it times with saline,
sedimented, and then added to this antiserum. This was repeated and
the agglutinin titer determined after each absorption»

At the end of

the 7th absorption, only slight and doubtful agglutination was observed
in 1*2 and l;lt dilutions.

This antiserum was then filtered through a

No. 12 Handler bacterial filter and stored in the frozen state (-20° C).
B, Non-specific absorption with normal mouse liver and spleens
Liver and spleen obtained from 3 normal CFW female mice (about 5-'week
old) were washed twice with saline and then cut into small pieces.
These pieces were washed once with saline and then sedimented from
saline suspension by centrifuging at 5^000 rpm for 15 min. These
sedimented pieces were then added to 12.0 ml of rabbit antiserum
(titer 1:1,280) and mixed thoroughly. This suspension was allowed to
stand in the refrigerator. After 2h hours, the antiserum was separated
by centrifuging at 5,000 rpm for 20 min and fresh liver and spleen
pieces (washed with saline) obtained from 3 female CFW mice were added
to it.

This suspension was allowed to stand in the refrigerator for 2k

hours and at the end of this period the antiserum was separated. The
absorption was repeated 7 times. At the end of the 7th absorption, the
agglutinin titer was found to be 1&512.

The dilutions showing maximum

-22agglutination

were found to be l*l60 and 1:320.

This absorbed

antiserum was filtered through a No. 12 Handler bacterial filter and
stored in the frozen state (-20° C),

CHAPTER IV

EXPERIMENTAL RESULTS
I. Preliminary studies?
Experiment 1. Minimum number of tumor cells necessary to produce
ascites in female GFW mice. Two dilutions of ascites fluid were made
in saline, one containing 1,000 and the other 20,000 cells per ml.
These suspensions were injected into mice in varied doses as showi in
Table I. Mice in group I were injected with 0,2 ml of the cell
suspension containing 1,000 cells per ml, or 200 tumor cells per mouse.
All other groups were injected with varied amounts of the suspension
containing 20,000 cells per ml. It is evident from the results in
Table I that the time required by the tumor to manifest itself in the
form of recognizable ascites varied inversely with the number of tumor
cells in the transplant. With a dose of 200 cells ascites was notice
able on the 28th day in only 3 of 10 mice injected. With a transplant
of 16,000 tumor cells, however, ascites was noticed in a few mice by
the 6th day after the challenge, and 10 of 10 mice developed ascites
by the l^th day.
Experiment 2. Comparative susceptibility of female mice of the
GFW and CFl strains, Tumor fluid obtained separately from CM and CFl
mice was used for challenging the tro breeds of mice.

Cell suspensions

with varied cell concentrations were injected into groups of 5 mice
as shown in Table II. The incidence of ascites was recorded on the
l^th and 28th day after the challenge. From the results in Table II,
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TABLE I
MINIMUM NUMBER OF TUMOR CELLS AND ASCITES

Group

No. of
calls

I
II
III
IV
V
VI

200
1000
2000
liOOO
8000
16000

Positives* on (days)
10th
iSth
20th

6th

8th

—

M

wm

#

•w

"

'

mm
mm

1/10

—

3/10

3/10
Vio

—

10/10
9/10
10/10

9/10
10/10
PAo
10/10

28th
3/10
U/5
10/10
10/10
9/10
10/10

31st
7/10
10/10
10/10
9/10
10/10

* Mice that showed growth of timor in the form of obvious ascites are,
hereafter, mentioned as "Positives,"

TABLE II
COMPARATIVE SUSCEPTIBILITY OF CFl AND CFI MICE

Group

Challenge
(No. of ce Us
in thousands)

I
II
III
]T

1
2
k
8

CFI
CFW
No. of positives on 28th
day
5/5
5/2
5/5
5/5

k/5
k/5
5/5
5/5
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there appears to be no marked difference in the susceptibility of the
two strains of mice. However^ in general, the CFl mice appeared to be
slightly more susceptible than the GFW strain.
Experiment 3«

Growth curve of the Bhrlich ascites tumor and

differential blood count on the tumorous mice. Seventy female Hamilton
mice, each about 5- to 7-week old, were injected with 0.2 ml of the
ascites fluid obtained from female Hamilton mice in which the tumor was
10 days old. Groups of 5 mice were bled from the infra-orbital sinus
on the desired day and smears made. These smears were stained with
Wright's stain and differential white-blood-cell counts performed.
After the fourth day of challenge when the ascites became manifest, 5
mice were randomly selected daily, tapped for ascitic fluid, then bled
and discarded. Daily cell counts were performed on the tumor fluid
thus obtained. The averages of the cell counts of fluids obtained
from 5 different mice at the various time intervals investigated were
plotted (Fig, 1). Differential white-blood-cell counts were performed
on each of five smears and the results were averaged and plotted
(Fig. 2).
It is evident from Fig. 1 that the tumor cell count of the ascitic
fluid per unit volume was highest from ^ to 7 days after the tumor
transplantation. At this time the cell count was found to be around
15-20 X 10^ cells per ml. Thereafter, the cell count per volume
decreased progressively until about the liith day when it was as low as
7 X lo7 cells per ml. The ascites, however, progressed and the

-27FIGURE 1.
T
TUMOR CELL COUNT OF THE ASCITES FLUID PER UNIT VOLUME

8

ir\ '
H

O
r-i

m'

o O"

8

10

11

12

13

Time in days after tumor transplantation.

14

-2Ô-

FIGURS 2

DIFFERENTIAL W.B.C. COUNT ON BLOOD SMEARS OP TUMOROUS MICE
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-29abdoiJien became more and more distended, till about the 18th to 20th day
when the animals died.
The differential blood count (Fig. 2) showed a progressive rise in
the neutrophils and a progressive decrease in lymphocytes. Eosinophils
showed no noticeable change.

The large monocytes increased gradually,

reaching the highest percentage (20%) on the 11th or 12th day.

II, Active specific immunization:
Experiment

Lowest concentration of formalin required to kill

the tumor cells. A tumor cell suspension with a cell count of 5 x 10
cells per ml was mixed with 2,0% formalin in saline, and saline in
different proportions to obtain the desired concentration, as shown in
Table III. Then the mixture was allowed to stand at room temperature
for 1 hour. After this period, it was kept in the refrigerator for l6
hours. At the end of l6 hours, it was injected into female Hamilton
mice in doses of 0.2 ml per mouse. An untreated cell suspension with
the same cell count was used as control. The number of mice that
developed ascites was recorded on the l5th day after the injection.
The results in Table III show that a concentration of formalin between
0.25 and 0.125% was required to kill the tumor cells, From these
results it was decided to use 0,2% formalin solution to prepare vaccines.
Experiment 5»

Immunization of mice with formalin-killed cells.

Formalin-treated cells were prepared as described in the section on
materials and methods, and injected intraperitoneally in female CFW
mice in 0.2 ml doses. Three inmunizing injections were given at four-
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TABLE III
EFFECT OF FORMALIN ON THE TUMOR CELLS

Formalin

2%

Call suspension

2.0 ml
1.0 ml
1.0 ml
0.5 ml

2,0
2.0
2.0
1.0

ml
ml
ml
ml

Controls

cells on]y

Saline
1.0 ml
^.0 ml
6.5 ml

Final
concentration

Positives
total mice

1%
0,5%

O/k
O/h

0.2$$
0.125$

0/1+
2/k

h/h

-31day intervals. Then the mice were divided into 3 groups. Group I was
challenged 6 days after the last injection, group II, 10 days, and
group III, lii days after the last vaccination. The challenging dose
consisted of 5,000 tumor cells. Observations as recorded on the 20th
day after challenge are shown in Table IV, The results show that the
induced immunity increased with time after the last vaccination. It
was most marked on the li^th day after the last vaccination, when only
19.8% of the mice developed the tumor as compared to 72,5 and ii2,5^
on the 6th and 10th day, respectively.
Sjçeriment 6»

Lowest concentration of phenol required to kill the

tumor cells, A tumor cell suspension with cell count of 5 x 10^ per ml
was prepared and mixed with varying amounts of 1% phenol in saline, and
plain saline in order to obtain the desired concentration of phenol
according to the protocol in Table V, The suspension was kept at room
tenperature for one hour and in the refrigerator for 16 hours. At the
end of this period, the cells were separated from the phenol solution
by centrifugation at 2,000 rpm for 5 min and then washed once with
saline to remove the excess phenol.

The sedimented cells were resus

pended in saline, TWo-tenths ml of this suspension was injected
intraperitoneally into each mouse. Washed tumor cells not treated with
phenol were used as controls. The results indicated that the lowest
concentration of phenol that was required to kill the tumor cells under
the specified conditions was between 0,5 apd 0,8%, Therefore, 0,8%
phenol was employed to prepare the vaccines.
Experiment 7. Immunization of mice with phenol-killed tumor cells.
Pour intraperitoneal injections of phenol-killed vaccine were given at
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TABLE IV

IMMimiZAIION WITH FOBMALDJ-KILLBD CELLS

Group
I
la control
II
Ila control
III
Ilia control

No. of
vaccn.
3
M
3
mm

3

Time of challenge
after last vaccn.
6
6
10
10
lU
14

days
days
days
days
days
days

Positives
total mice
29/kO

5/5
17/Lo

V5
6/30
30/30

% Positives
72.5^
100,0*
12.52
80.0%
19.8%
100.0%
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mBLE V
EFFECT OF PHENOL ON TUMOR CELLS

Gfcroup
I
II
III
I?
V
VI
control

Phenol
1%

Cell
suspension

5.0 ml

cells
1.0
.1.0
2,0
2,0
2,0

U»0
2.0
1.0
1.0
mm

ml
ml
ml
ml

frcm
ml
ml
ml
ml
ml

cells only

Saline

—

—

1,0 ml
S,0 ml
—*

Pinal Positives
concn. total mice
1.0%

0/5

0.8*
0.#
0.22%
0.125$

q/5

—

5/5
vs

-jltb-day intervals. Fourteen days after the last vaccination, the mice
were challenged with 5jOOO tumor cells. The results on the 20th day
after the challenge are given in Table VI. The protection resulting
from the administration of phenol-killed vaccine was weak.
Experiment 8. Lowest concentration of merthiolate required t_o
kill the tumor cells.

Tumor cell suspension with 5 x 10^ cells per ml

was prepared and mixed with 1:1000 merthiolate solution and saline in
varying proportions as shown in Table VII in order to obtain the
desired concentration of merthiolate. This suspension was kept at
room tençierature for one hour and then in the refrigerator for 16
hours. It was then injected intraperitoneally in mice in doses of
0.2 ml per mouse. Washed untreated cells were used as controls.

The

results in Table VII show that a merthiolate concentration of IsSOOO
was the lowest concentration that would kill the tumor cells under the
specified conditions. This concentration was employed for killing
tumor cells in the preparation of vaccines.
Experiment 9. Immunization of mice with merthiolate-killed tumor
cells. Three intraperitoneal injections of 0.2 ml of the merthiolatekilled cells were given at U day intervals. Fourteen days after the
last immunizing injection, the mice were challenged with 5#000 tumor
cells.

The results recorded on the 20th day after the challenge are

shown in Table VIII.

Only 11 of the 30 immunized mice developed .the

tumor after c&allenge while 30 of 30 control mice developed the tumor
after a similar challenge.
Experiment 10. Minimum dose of ultraviolet light required to kill
the ascites tumor cells. Ten ml aliquots of a 1:100 dilution of the

TABLE VI
BfflRMIZATION WITH PHSMOL-KILLED TUMOR CELLS

Group
I
II

No. of
vaccn.

Positives
total mice

It
-

29A0
39A0

% Positives
72.5$
97.5^
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TABLS VII
EFFECT OF MBBTHIOLATB ON TUMOR CELLS

Group
I
II
III
17
V
control

Merthiolate
lilOOO
2,0
1.0
1.0
0.5
-

ml
ml
ml
ml

Cell
suspension

Saline

Final Positives
concn. total mice

.2.0
2.0
.2.0
1.0
cells

2.0 ml
7.0 ml
6.0 ml
-

1:2000
ItSOOO
1:10000
1:15000
-

ml
ml
ml
ml
only

0/5
0/5
1/5
5/5
5/5
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TABLE VIII
IMMUNIZATION WITH MERTHIOLATB-KILLBD TIMOR CELLS

^
Group
I
II
controls

No. of
vacon»

Positives" ^
total mice

3
-

11/30
30/3a

% Positives
36.3%
100.0$

-38ascitic fluid were exposed in Petri dishes to ultraviolet light for
different lengths of time as shown in Table IX, Two-tenths ml of this
ultraviolet-treated fluid was injected intraperitoneally into mice
within 30 min after irradiation.

Unirradiated fluid containing the

same concentration of cells was used as a control. An exposure of 10
min or more was required to kill the tumor cells. Ten and fifteen min
exposures were ençloyed for the preparation of vaccines.
Experiment 11, Immunization of mice with ultraviolet light-killed
tumor cells. Four intraperitoneal injections of 0,2 ml of vaccines
irradiated for 10 and 1$ min were given at i|.-day intervals. Two weeks
after the last vaccination the mice were challenged with 5,000 tumor
cells. The results obtained on the 20th day after the challenge are
given in Table X, Only 5 of 30 mice vaccinated with tumor cells
irradiated for 10 min and only ij. of 30 mice vaccinated with the vaccine
irradiated for 15 min developed the tumor after challenge. All the 30
unvaccinated controls developed ascites.
Ill, Non-specific immunization;
Experiment 12, Non-specific immunity induced by incomplete
Freund's adjuvant mixture. Forty GFW female mice were injected intra
peritoneally with 0»2 ml of inconçtlete Freund's adjuvant mixture.
Another control group consisting of I4.O mice received sterile saline
instead of the adjuvant mixture, One week later both groups were
challenged with 5,000 tumor cells. Observations were recorded on the
20th and 28th days after the challenge.

The results shown in Table XI

indicate that Freund's adjuvant has a marked capacity to increase the
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TABLE IX
EFFECT OF ULTRAVIOLET LIGHT OM TUMOR CELLS

Group
I
II
III
IV
7
VI
control

Time of irradn.
in min
8
10
15
20
25
-

Positives
total mice
2/^
0/5
0/5
0/5
0/5
5/5

-&0—

TABLE X
IMMUNIZATION OF MICE WITH ULTRAVIOLET LIGHT IRRADIATED CELLS

Group
I

11
III
controls

Time of
irradn,
10 min
I5 min
-

Positives
total mice

% Positives

5/30

l6,5%

h/30

13.2%
100.0%

30/30
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mELE 21
EFFECT OF INCOMPLETE FREUND'S ADJUVANT

. Positives/total lio» of mice on
—

28th day

I
(F. Adjuvant)

. 3/10

^/ItO

II
(Saline)

3k/kO

39/hO

» Each group consisted of i|.0 female CFlff mice.

-42resistance of the mice toward an intraperitoneal challenge of the tumor.
Experiment 13. Duration of non-specific resistance induced by
incomplete Freund's adjuvant mixture.

Mice treated with 0.2 ml incom

plete Freund's adjuvant mixture were challenged with 5^000 tumor cells
at different intervals as indicated in Table XII.,

Mice treated with

saline instead of Freund's adjuvant served as controls.

The results

given in Table XII and Fig. 3 show that the protective effect of Freund's
adjuvant is not manifested until 5 to 8 days after its administration.
-On the 10th and l5th day the mice were highly resistant to the tumor.
These mice were actually immune to the challenge of 5^000 tumor cells
since they were still tumor-free 45 days after the challenge.
Experiment 14. Non-specific iianunity -Induced by zymosan. Fivehundredths gm (0,05 gm) of zymosan was suspended in 10.0 ml saline and
to 8.0 ml of this suepnsion was added 2.0 ml of saline.

This suspension

now contained 400 pgm of zymosan in 0.1 ml. Two-tenths ml of this
suspension was injected intraperitoneally into each mouse. The controls
received 0.2 ml of sterile saline. The mice were then challenged with
5,000 tumor cells at different intervals of time as shown in Table XIII.
The results (Table XIII and Fig, 4) indicate that the non-specific
inmiunizing effect of zymosan was highest when it was given simultane
ously with the tumor.

This effect decreased gradually until the seventh

day when little or no effect was demonstrable.
Experiment 15.

Non-specific immunity induced by killed Bordetella

pertussis cells. Two billion B. pertussis cells suspended in 0.2 ml of
saline were injected intraperitoneally into female CFW mice. The control
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TABLE XII

DUBATION OF EFFECT, OF INCOMPLETS FBEUMD'S ADJUVANT

Qroup

No. of
mice

I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII

10
5
10
5
10
5
10
5
10
5
10
5

Treated with
Adj. Saline

-2ii hrs

f
4"

+
«s»

•w-

+

+
—

+
—

+
-

Time of
challenge

+
am
+

No. of positives on
20th day
28th day
6/10

~2k hrs
0
0
2b
2I4.
5
5
10
10
15
15

hrs
hrs
his
hrs
days
days
days
days
days
days

6/10
5/^
6/10
S/^
6/10
0/10
5/5
1/10
5/5

7/10
5/5
7/10
5/5
6/10
5/5
6/10
5/5
0/10
5/5
1/10
5/5

* These mice were again observed on the U5th day after challenge. In
group H, one mouse had developed ascites while th$ other 9 did not*
In group XIj all the nine mice remained healthy at this time.
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FIGURE 3.

NON-SPECIFIC IMMUNIZING EFFECT OF INCOMPLETE FREUND*S ADJUVANT
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TABLE XIII

NON-SPECIFIC IMMUNITY INDUCED BY ZYMOSAN

Group
I
II
III
IV
V
VI
VII
VIII

Treatment
No. of
zymosan saline
mice
10
10
10
10
10
10
10
10

"f
—

+

+

M*

-

+

+

+
-

—

i
4

Time of
challenge
0 hrs
0 hrs
2k hrs
2ii hrs
3 days
3 days
7 days
7 days

No. of positives on
20th day 28th day
o/io
10/10
lAo
lOAO
2/10
9A0
8/10
10/10

2/10
loAo
^/lo
10/10
2/10
10/10
8Ao
10/10

FIGURE 4

NON-GPEGIFIC IMMUNIZING SFFECT OF ZYMOSAN
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mice received 0,2 ml of saline instead of the B. pertussis cells.
Subsequently, these mice were challenged with 5,000 tumor cells at
different intervals of time as shown in Table XIV*

B. pertussis cells,

when injected simultaneously with or after the tumor had very little
effect in enhancing the defense of the mice towards the tumor challenge
(Table XIV and Fig. 5). However, there was a progressive increase in
immunity until the 5th day after B. pertussis treatment when 8 of 10
mice did not develop ascites on the 20th day after challenge and 6 of
10 mice did not show any evidence of tumor growth on the 28th day after
the challenge. This protective effect of B, pertussis decreased after
5 days, and little protection was observed 18 days after B, pertussis
treatment.
Experiment 16»

Non-specific immunity induced by Escherichia coli

lipopolysaccharide »

Two and five-tenths mg of the endotoxin were dis

solved in 25.0 ml of saline. This solution contained 100 |agm of
endotoxin per ml.

Two-tenths ml of this solution containing 20 )igm of the

endotoxin was injected intraperitoneally into each mouse. The controls
were injected with 0.2 ml sterile saline.

These mice were challenged

with 5,000 tumor cells at different intervals of time as shown in
Table XV, As is evident from the results in Table XV and Fig. 6, there
was an increased resistance to tumor transplants when the lipopolysaccharide was given simultaneously with, or 2k hours after the challenge.
This protective effect was still noticeable 21^ hours after the adminis
tration of the endotoxin, but decreased progressively thereafter, until
the 10th day when little or no protection could be demonstrated.
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TABLE XIV

N0N-3PSGIFIC IMMUNITY INDUCED BY B. PEETHSSIS CELLS

Treatment
Group* B» pertussis Saline
I
II
III
17
V
VI
VII
VIII
IX
X
XI
XII

+
+

+

+
+

mm

4

+
«M

+
f-

+

+

Time of
challenge
-2U hrs
-2k hrs
0 hrs
0 hrs
5 days
5 days
8 days
8 days
12 days
12 days
18 days
18 days

* Each group consisted of 10 female CF¥ mice

No. of positives on
20th day
28th day
7/10
10/10
5Ao
10/10
2/10
10/10
6Ao
10/10
3/10
10/10
6/10
10/10

9/10
10/10
7/10
10/10
4/10
10/10
6/10
10/10
S/10
10/10
6/10
10/10
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NON-SPECIFIC IMMUNIZING EFFECT OF B. pertussis CELLS

-1
0

r
1

»

1

1

r

I

r——1—il

2
3
4
5
6
7
8
Time in days after B. pertussis*

i
1 2

Vj

»
1 8
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TA^ 27
NON-SPECIFIC IMMUNITY INDUCED BY 3. COLI ENDOTOXIN

Group*
I
II
III
IV
V
VI
VII
VIII
IX
X

Treatment
saline
endotoxin
4—

+

+
a*

+

4
aw

+

f

•M.

».

+

-Î*

—

•h

Time of
challenge
-Zk
-2Ù
0
0

2k
2li
5
5
10
10

hrs
hrs
hrs
hrs
hrs
hrs
days
days
days
days

No., of positives on
20tn day
28th day
Vio
6/10
vs
6/10
5/5
7/10
5/5
8Ao
5/5

6/10
5/5
8/10
5/5
10/10
5/5
9/10
5/5
9/10
5/5

* The controls (groups II^ IV^ ¥1, VIII and X) consisted of 5 mice in
each groupJ whereas the other groups consisted of 10 mice.
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NON-SPECIFIC IMMUNIZING EFFECT OF E. coli ENDOTOXIN
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IV. Effect of rabbit antiserums
Experiment 17. ^ vitro neutralization of the tumor by rabbit
antiserum, A 1;80 dilution of rabbit antiserum (agglutinin titer
1/2560) which produced strong agglutination

was used. Washed and

sedimented tumor cells were resuspended in this dilution to obtain a
final concentration of 20,000 cells par ml. As a control a similar cell
suspension was prepared in normal rabbit serum obtained from the same
rabbit before immunizing injections were given. A second control con
sisted of a saline suspension containing 20,000 tumor cells per ml.
These 3 suspensions were incubated in a water bath at 37° C for 1 hour.
Half an hour later the tubes were shaken and 0.2 ml of the corresponding
suspension injected into each of 10 mice. The results were recorded on
the 20th and 28th days after challenge (Table XVI)»

These results show

that the tumor cells are almost completely neutralized after incubation
with the antiserum, while not affected by normal rabbit serum or saline.
Experiment 18. Passive immunization with rabbit antiserum. Sixty
female CFHf mice were divided into 6 groups of 10 mice each. They were
all challenged with U,000 tumor cells, and subsequently given 1 to 5
intraperitoneal injections of 0.1 ml of the undiluted antiserum (titer
1/2560) at different intervals as shown in Table XVII.

The results,

recorded on 20th and 28th day after the challenge, indicate that treat
ment with antiserum 2k hours before the challenge had only slight pro
tective effect, but two or more injections given on 0 and 1 day after
the challenge, completely protected mice against the tumor transplant.
Normal rabbit serum and saline failed to produce this effect.
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TABLS XVI
IN VITRO NEUTRALIZATION WITH ANTISERUM

Group
I
II
III

Cells
treated with

Positives
total mice
20th day

antiserum
N.R.3.
saline

* Each group contained 10 female GFE mice.

lAo
loAo
10/10

Positives
total mice
28th day
1/10
10/10
10/10

TABLE XVII
PASSIVE IMMTOI2ATIQN IRITH ANTISBfflJM

Time of injecting the reagent
4 days
Group -2k hrs 0 hr
1 day
2
Antiserum;
I
+
II
III
IV
V
—
VI
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1
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—
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mm
I
+
II
f
-»
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+
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+
V
+
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I
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III
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7
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No. of positives on

+
+•
+
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f
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5
5
5
5
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5
5
5
5
5
5
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,55Experiment 19. Neutralization of the tumor with antiserum absorbed
with washed tumor cells. Babbit antiserum absorbed with tumor cells
(as described in the section on Materials and Methods) was used, A
1;80 dilution of this absorbed antiserum was prepared and in it were
suspended washed tumor cells to make a final cell concentration of
20,000 cells per ml. Similar suspensions were prepared in Is80 dilu
tions of agglutinating and normal rabbit serum, to be used as controls.
These cell suspensions were incubated at 37° C in a water bath for 1
hour and 15 min later were injected intraperitoneally into mice (0.2 ml
per mouse). The results obtained on the 20th, 28th and Uoth day after
challenge are shown in Table XVIII, These results show that antiserum
absorbed with tumor cells failed to neutralize the oncogenic property
of the tumor cells.
Experiment 20. Passive immunization with heated and specifically
absorbed antiserum. Groups of 10 mice were challenged with 5,000 tumor
cells and subsequently given 3 intraperitoneal injections of 0,1 ml of
the respective antisera at 0, 2k and 72 hours after the tumor trans
plantation. Agglutinating antiserum heated in a water bath at 56° C
for 1 hour was used as heated antiserum. The results shown in Table XIX
indicate that no passive immunization was possible with the absorbed
antiserum. Heated antiserum, however, retained its immunizing property.
Experiment 21. In vitro neturalization with non-specifically
absorbed antiserum.

Rabbit antiserum absorbed with normal mouse liver

and spleen (as described in the section on Materials and Methods) was
used for this experiment as well as experiment No. 22. Normal rabbit
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TABL2 ZVIII
EFFECT OF SPECIFICALLY AB03RBED ANTISERUM

Group
I
II
III

C e l l s P o s i t i v e s / t o t a l no. of mice on
treated with
20th day
28th day
IjOth day
Antiserum
Absorbed
antiserum
N.R.S.

O/lO

O/lO

O/lO

8/10
10/10

9/10
10/10

9/10
10/10

-^7-

TABLE XIX
EFFECT OF HS&TSD AND ABSOBBED ANTISSEQU

Group
I
II
III
IV
7

Cells
treated Tsrith
Antiserum
Heated
antiserum
Absorbed
antiserum
N.R.S.
Saline

Positives/total no. of mice on
20th day
28th day
Loth day
0/10

0/10

0/10

0/10

0/10

1/10

9/10
10/10
10/10

10/10
10/10
10/10

discarded
discarded
discarded

-S8serum and specifically absorbed antiserum were used as controls. The
dilutions used were IjlO and 1:120.

The results shown in Table XX

indicate that non-specific absorption of the antiserum lowered its
ability to neutralize the tumor cells, but did not render it conpletely
inactive.
Experiment 22. Passive immunization with non-specifically absorbed
antiserum»

The antiserum used was the same as for experiment 21, above.

Groups of 10 mice were challenged with 5^000 tumor cells and subsequnently
treated with the respective serum.

Three injections of 0.1 ml of the

serum were given 0, 2k and 72 hours after the tumor transplant.
Controls were treated with unabsorbed, specifically absorbed and normal
rabbit serum. The results shown in Table XXI indicate that non
specific absorption did not affect the protective power of the antiserum
when compared to that of the unabsorbed antiserum.
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TABLE XX

IN VITRO EFFECT OF NON-SPECIFIC ABSORPTION

Group
I
II
III
IV
V
VI
VII
VIII

Cells
treated with
lîlO^
(Antiserum
1:120)
lllOx
, (Sp. absorbed
(antiserum
ltl20)
IÎION
/Non-nsp, abs.
(antiserum
ltl20)
lilO'N
\N.R.S.
1*120)

Positives/total no. of mice on
20th day
28th day
l^Oth day

0/5
0/5

0/5
0/5

%

5/5

5/5

discarded
on 28th day

5/5

5/5

1/5

3/5

3/5

V5

V5

V5

5/5
5/5

5/5
5/5

discarded
on 28th day
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TABLE m
IN VIVO EFFECT OF NON-SPECIFIC ABSORPTION

Group
I
II
III
IV

C e l l s P o s i t i v e s / t o t a l no, of mice on
treated with
20th day
28th day
LOth day
Antiserum
Sp. absorb.
antiserum
Noa-sp. abs.
antiserum
N.R.S.

O/lO
7/10
O/lO
5/10

l/lO
5/10
10/10
discarded
2/10
10/10
discarded

CHAPTER V
DISCUSSION
The experimental results seem to indicate that tumor cells treated
with ultraviolet light, formalin and merthiolate (thimerosal) can induce
immunity against a subsequent challenge of about 5,000 tumor cells.
Ultraviolet light gave the best results (about 80% protection). In
demonstrating this immunity one has to bear two facts in mind;
1) actively immunized mice may tolerate only snail challenge doses
since the induced immunity may not be sufficiently strong to protect
the animals against heavier challenges, and 2) the time after immuni
zation, at which the challenge transplant is given is inportant because
the induction of immunity is a gradual process, which reaches its
maximum level at different times depending on the type of antigen, the
amount given, the route of administration and perhaps other factors.
The time factor is illustrated by the results obtained with formalinized
vaccines. A challenge given 6 days after the last vaccination was
tolerated by 27.2% mice, whereas that given on the llith day was toler
ated by 80%,
In order to explain the possible mechanism of action of agents
which render the tumor cells capable of inducing active immunity, one
should consider the homograft reaction. Apparently, the tumor grows
and kills the host because it fails to evoke the antibody response
necessary for its rejection. This may be due to the fact that the gen
etic make-up of the tumor cells is such as to make them an isologous
transplant rather than a heterologous or homologous transplant.
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-62According to the genetic concept of the transplantation reaction intro
duced by Gorer (itS), any agent that is able to alter the genetic make
up of the tumor cells in such a way that it becomes non-allelomorphic
to the normal mouse tissue, will render the tumor cells antigenic to
the mouse.

The previous experiments with x-rays (62) and nitrogen-

mustard (63), and our observations with ultraviolet light and formalin,
seem to indicate that all these agents that have been employed success
fully for immunization experiments, belong to the same group of agents
called "mutagenics" (90). If mutations were responsible for this
change in antigenicity, one would expect the tumor cells to multiply
after they have been treated with the agent.

This might be true at

least in case of the x-irradiated tumor cells (89).
Another possible mechanism by which immunity could be induced
would involve the presence of an active antigen in the tumor cells to
which the host may develop antibodies.

In normal mice these antibodies

will not develop rapidly enough to protect the animal against the
rapidly multiplying tumor cells.

However, according to this hypothesis,

any agent that is able to destroy the carcinogenic property of the
tumor cells without affecting the "specific protective antigen," could
convert the tumor cells into a vaccine capable of protecting the
animal against subsequent transplants. That this hypothesis may indeed
be true is indicated by the reports demonstrating specific antibodies
in animals with actively growing tumor cells (52, 53), and in rabbits
immunized with specific antigens obtained from neoplasms (5L, 55).
Specific neutralizing antibodies have also been demonstrated in chickens

-633 to 5 weeks after the regression of Rous sarcoma (5l). The main
difficulty here appears to be the fact that in the presence of actively
growing tumor cells it is difficult to demonstrate specific antibodies,
although they have been demonstrated against Shope Papilloma and BrownPearce Carcinoma in rabbits (52, 53)*
Still another possible way in which these vaccines could stimulate
immunity is through a non-specific host-defense mechanism.

Earlier

work by Pellimer, Landy and Shear (69), has shown that tissue-polysa ccharides derived from normal and malignant (Sarcoma 37 and Carcinoma
21:1-6) mouse tissue, have the property of increasing the host resistance
to bacterial infections by altering the serum properdin levels.
Repeated injections of killed tumor cells may cause this effect. The
fact that non-specific immunity would ordinarily not be expected to
offer complete protection in as great a percentage of mice as specific
immunity would, bears but little significance in view of the non
specific immunity that has been induced through treatment with incomplete
Freund's adjuvant mixture in our experiments.
The fact that phenol-killed and merthiolate-killed tumor cells
produced only weak immunity, can probably be explained by assuming that
these agents destroyed or altered the antigenicity of the tumor cells,
so that they were not capable of evoking a stror^ antibody response.
Results with agglutinating antiserum prepared in rabbits indicated
that this antiserum was capable of neutralizing to vitro the carcino
genic property of the tumor cells. This agrees with the results of
Flax (80), This antiserum also protected mice against a challenge of

-61*.5,000 tumor cells if 3 or more intraperitoneal injections of 0,1 ml of
the antiserum were given»

This protective property of the antiserum was

lost after repeated absorption with tumor cells, strongly suggesting the
presence of specific antibodies to the tumor. Specifically absorbed
antiserum also lost its agglutinating capacity, while antiserum absorbed
with normal mouse tissues still retained the agglutinins as well as its
protective properties against the tumor.

Earlier results of Flax (80)

and Horn (81) indicated that treatment of mice with antiserum only
prolonged their survival period.

The challenge used by these workers

was large (0,1 ml of the tumor fluid or about 1 x 10^ tumor cells per
mouse). In our e^çieriments complete protection was obtained with a
challenge dose of 5,000 tumor cells.

Contrary to the findings of Flax

(80), guinea pig complement was not found necessary to show ^ vitro
neutralization of tumor cells. In the present work it has been clearly
shown that normal rabbit serum does not have the capacity to neutralize
the tumor cells either to vitro or to vivo.
The antiserum prepared against washed tumor cells will certainly
be expected to contain antibodies against normal mouse tissue, since
the mice used were not genetically homogeneous. The role that these
antibodies might have played in the present work was ruled out by
absorbing the antiserum with normal mouse tissue and showing that its
protective property was not removed to this way. The results obtained
by Horn (81) indicated that antisera prepared against normal mouse
liver and spleen tissue had no neutralizing effect on the Shrlich
ascites tumor cells. This in conjunction with our observation that

-65absorption of the antiserum with tumor cells removed the agglutinating
as well as neutralizing power of the antiserum, favors the postulation
that specific antibodies may be responsible for the protective activity
of the immune serum.
From the results presented in this thesis, it is also evident that
in addition to specific immunization, non-specific agents also are
capable of producing immunity to Ehrlich ascites tumor. Bacterial
endotoxins and lipopolysaccharides from plant and animal sources have
been known to alter the resistance of the host towards infections if
given in very small doses (70, 71, 72, 73). In our experiments,
zymosan, E. coli endotoxin, B. pertussis cells and incomplete Freund's
adjuvant appeared to increase the resistance of mice towards subsequent
tumor transplants.

Not only the survival time was prolonged, but in

the case of Freund's adjuvant, the mice appeared to tolerate coupletely
a challenge of 5,000 tumor cells.

The mechanism involved here is not

yet known. Various host defense mechanisms have been incriminated.
The increase in lysozyme, properdin and phagocytic acitivity of cells
have been chiefly considered. As shown by Hook and his co-workers (87),
the serum lysozyme and properdin levels showed an initial drop followed
by a marked rise after an intraperitoneal injection of 1,0 mg of
zymosan in mice. Serum lysozyme did not rise above normal levels until
about the 3rd day after the administration of polysaccharide.

The

properdin level took still longer to show a rise above normal. Ten
days after the administration of zymosan, the properdin level was about

l60% of normal values, and remained high for about 32 days. The serum
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lyaozyma level dropped after about 16 days. Earlier work of Pellimer,
Landy and Shear (6^), had shown that the injection of tissue polysac
charides derived from animal tissues led to a rise in properdin level
noticeable 12 to 2k hours after administration of the polysaccharide.
The results obtained with zymosan and E, coli endotoxin could possibly
be explained on this early rise of properdin level. In the case of
Freund's adjuvant and B, pertussis, this explanation does not seem to
apply. However, according to Hook et al. (87), properdin and lysozyma
level and the leukocyte count showed marked rise only about 7 days
after zymosan injection, and the properdin level remained high for 32
days. If this is the case when Freund's adjuvant is injected, the
properdin system might well explain the protective activity of this
agent. The protective effect of B. pertussis may be different.
Properdin level might not be the only factor involved, however, since
Hook et al. (87) have shown that after the administration of zymosan,
the properdin level reached its peak 10 days after injection of the
substance and it remained high for about 30 days. The protection
against Zhrlich ascites tumor obtained in the present work did not
follow this pattern except in the case of Freund's adjuvant.
It is interesting to note that the protection produced by the
agents-tested, did not manifest itself at the same time. With zymosan,
for example, the protective effect was demonstrated within 2h hours, and
disappeared after 6 days. With B, pertussis cells, the maximum protec
tion was noticed on or about the 6th day, while with Freund's adjuvant
the protection was marked only 7 days after and persisted for at least

-6715 days.

These facts seem to suggest that more than one non-specific

mechanism may be involved for these agents. A study of serum properdin
level, lysozyme level and the phagocytic index following the administration of these agents is suggested. This may give a clue to the
probable mechanism of action of these non-specific substances.

CHAPTER VI

swmM
Attempts were made to induce active imimmity in female Swiss
Webster mice against Ehrlich ascites tumor by the use of tumor cells
treated with formalin, merthiolâte (thimerosal), phenol and ultraviolet
irradiation as vaccine. This immonity was tested against an intraper
itoneal challenge of 5,000 tumor cells given 2 weeks after the last
immunizing injection.

It was found that cells treated with ultraviolet

irradiation produced maximum protection (86,8^). With formalin- and
merthiolate-treated cells, the protection obtained was 80.2$ and 63.7#
respectively.

Only weak protection (27.5^) was obtained with cells

treated with phenol.
Non-specific immunizing effect of incomplete Freund's adjuvant
mixture, zymosan, killed B. pertussis cells and 2. coli endotoxin was
also studied. It was found that 9 of 10 mice that received 0,2 ml of
the adjuvant mixture intraperitoneally were completely immune to an
intraperitoneal challenge of 5,000 tumor cells. This protective effect
was noticeable 7 days after the administration of the oil mixture and
persisted for at least 15 days.

With zymosan, this effect was demon

strated within 2k hours after intraperitoneal injection of 800 pgm of
the polysaccharide and disappeared after 6 days. Five days after an
intraperitoneal injection of 2 billion merthiolate-killed B. pertussis
cells, 8 of 10 mice were found to be more resistant to a transplant of
5,000 tumor cells as compared to the mice that did not receive B,
pertussis cells.

This effect was found to be decreasing after the 5th
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-69day but was still noticeable 18 days after the injection of B, pertussis
cells, S. coli endotoxin, when given intraperitoneally in doses of
20 pgm. Tuas found to increase slightly the resistance of mice.

This

effect became noticeable with a challenge given 2k hours before the
endotoxin and persisted till 10 days after»

However, from the results

with E, coli endotoxin it appeared that the immunity stimulated by the
endotoxin was expressed only by prolonging the appearance of ascites
and survival time of the mice. Many of the mice that did not show
any ascites on the 20th day were found to develop ascites on the 28th
day, Freund's adjuvant on the other hand, appeared to produce complete
protection against the challenge used since the mice did not show
any ascites even hë days after the challenge. In mice immunized with
zymosan and B, pertussis cells, a comparison of the results on the
20th and 28th day appeared to indicate some degree of complete
protection as many of these mice did not show any ascites on the 28th
day which was the last day of observation.
It was found that rabbit antiserum to tumor cells was able to
neutralize in vitro the carcinogenic property of the Ehrlich ascites
tumor cells if they were incubated in an appropriate dilution (ls80)
at 37° C for 1 hour. It was also possible to passively immunize mice
with 3 or more intraperitoneal injections of 0,1 ml of the antiserum,
against a transplant of ^,000 tumor cells. Absorption of this anti
serum with tumor cells resulted in loss of both ^ vitro and

vivo

neutralizing properties. Non-specific absorption with normal mouse

-70liver and spleen resulted in a decrease in the agglutinin titer (from
1;1280 to 1*S12) but did not appear to affect its property to neutralize
tumor cells either in vitro or

vivo. It was also found that haating

the antiserum at 56° C for 1 hour did not affect its agglutinating or
neutralizing property.
The probable mechanisms of action of these specific and non
specific immunizing agents were discussed.
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